Last reviewed · How we verify
Blood-stage controlled human P. falciparum malaria infection
Blood-stage controlled human P. falciparum malaria infection is a Biologic drug developed by University of Oxford. It is currently in Phase 1 development.
At a glance
| Generic name | Blood-stage controlled human P. falciparum malaria infection |
|---|---|
| Sponsor | University of Oxford |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fever
- Headache
- Chills
- Decreased appetite
- Nausea
- Malaise
- Fatigue
- Myalgia
- Dizziness
- Diarrhea
- Palpitations
- Lymphadenopathy
Key clinical trials
- A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate (PHASE1)
- VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection (EARLY_PHASE1)
- A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) (PHASE1)
- A Study of Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection in Tanzania (NA)
- Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 (NA)
- Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent (PHASE1, PHASE2)
- VAC063C: A Study to Assess Repeat Blood-stage P. Falciparum Infection (NA)
- Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Blood-stage controlled human P. falciparum malaria infection CI brief — competitive landscape report
- Blood-stage controlled human P. falciparum malaria infection updates RSS · CI watch RSS
- University of Oxford portfolio CI
Frequently asked questions about Blood-stage controlled human P. falciparum malaria infection
What is Blood-stage controlled human P. falciparum malaria infection?
Blood-stage controlled human P. falciparum malaria infection is a Biologic drug developed by University of Oxford.
Who makes Blood-stage controlled human P. falciparum malaria infection?
Blood-stage controlled human P. falciparum malaria infection is developed by University of Oxford (see full University of Oxford pipeline at /company/university-of-oxford).
What development phase is Blood-stage controlled human P. falciparum malaria infection in?
Blood-stage controlled human P. falciparum malaria infection is in Phase 1.
What are the side effects of Blood-stage controlled human P. falciparum malaria infection?
Common side effects of Blood-stage controlled human P. falciparum malaria infection include Fever, Headache, Chills, Decreased appetite, Nausea, Malaise.